BICX · BioCorRx Inc.
$0.25
+0.02 (+10.62%)
At close · Oct 12
View the 10-Q filed Aug 14, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash of $21,237 and working capital deficit of $8,231,326. During the six months ended June 30, 2026, the Company used net cash in operating activities of $873,260. The Company has incurred net losses since inception. These conditions raise substantial doubt about the Company's ability to continue as a going concern for the next twelve-month period since the date of the financial statements were issued.”View the 10-Q filed Aug 14, 2026
Customer concentration
— top 2 customers 100% of revenue
2 customers — 100% of revenue (three months ended June 30, 2026)
“The Company's revenues earned from sale of products and services for the three months ended June 30, 2026 included 100% from two customers of the Company's total revenues.”
2 customers — 99% of revenue (three months ended June 30, 2025)
“The Company's revenues earned from sale of products and services for the three months ended June 30, 2025 included 99% from two customers of the Company's total revenues.”
Market Cap
$7.44M
Shares
29.76M
Volume · Oct 12
6724
Avg daily vol (3M)
5415
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.25
Open$0.25
Day$0.25–0.25
52W close$0.16–0.50
Avg vol 30d4K
Short int11K · 0.0% float · 11.7d
Short vol100%
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$786,616
Trailing 12 months
Net income (TTM)
−$3.15M
Trailing 12 months
Revenue growth YoY
-50.6%
Year over year
Operating margin
-623.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+71.8%
Year over year · more shares
Price change (1Y)
-44.4%
Trailing year
Short interest
0.0%
Latest settlement · 11.7 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−8%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
27%
mid-range
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−46%
trailing
YTD return
−14%
this year
Relative strength
−56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.04% of float · ▲ +4.3% MoM · 11.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
+10301%
Y/Y
Gross margin
70%
contracting
EPS growth
+61%
Y/Y
Free cash flow
$-2.3M
Balance sheet
$68.6K
net cash
Quant / Vol
risk profile
Volatility
340%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
27%
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.04% of float · ▲ +4.3% MoM · 11.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 27%
Range high $0
vs 200-day avg -26%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BICX
this stock
BioCorRx Inc.
|
$7.44M | -14.1% | +10301.1% | — | 0.0% |
|
HCA
HCA Healthcare, Inc.
|
$100.91B | -0.2% | +7.1% | 15.3 | 2.2% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.52B | -11.7% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.45B | +37.0% | +0.9% | 10.3 | 2.3% |
|
EHC
Encompass Health Corp
|
$12.01B | +14.6% | +10.5% | 19.8 | 3.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- IFP Advisors, Inc
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BICX | +17.9% | +12.1% | -45.7% | +0.0% | -14.1% |
| SPY | +0.4% | +2.3% | +10.5% | +2.0% | +14.1% |
| vs SPY | +17.5% | +9.9% | -56.2% | -2.0% | -28.2% |